CDH1 and ovarian carcinoma: As shown in Fig. 5, mesenchymal marker β-catenin decreased, while epithelial marker E-cadherin increased in BI853520 treated ovarian cancer cells, which showed that BI853520 inhibits EMT process in ovarian cancer cells (Fig. 5C, D).